Vallapragada, V. V., Inti, G., Vidiyala, S. R., Jadi, S.
Lanthanum Carbonate is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). When given orally, Lanthanum Carbonate dissociates in the acid environment of the upper gastrointestinal tract to release lanthanum ions. The free lanthanum ions bind with dietary phosphate released from food during digestion to form highly insoluble lanthanum-phosphate complexes which prevent the absorption of phosphate, consequently reduce the serum phosphate. In order to evaluate the in-vitro binding capacity of lanthanum carbonate, a simple and efficient Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) method was developed and validated for determination of phosphate across the pH range encountered in the gastrointestinal tract. The binding parameter constants of Lanthanum Carbonate were determined using the Langmuir approximation for the dosage form at pH 1.2, 3.0 and 5.0 by Inductively Coupled Plasma-Optical Emission Spectrometry. The developed method is selective and capable of detecting phosphate in the presence of placebo matrix. The method has been validated with a lower limit of quantitation of 0.2 mM for Phosphate. A linear response function was established for the range of concentrations 0.2-80.0 mM (r>0.99) for Phosphate. The method was found to be simple, robust, sensitive, specific and accurate. It has been successfully applied for determination of phosphate binding to lanthanum carbonate over the human gastrointestinal pH range at different time points.
Binding parameter constants, ICP-OES, in-vitro phosphate binding study, Langmuir approximation, Fosrenol Tablets, Quantitation
Cite This Article
Vallapragada, V. V., Inti, G., Vidiyala, S. R., & Jadi, S. (2014). Comparison of Binding Parameter Constants between Lanthanum Carbonate Chewable Tablets and Fosrenol Tablets by a Validated Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES). International Journal for Pharmaceutical Research Scholars (IJPRS), 3(1), 718-731.